On February 9, 2016 OPKO Health, Inc. (NYSE: OPK) reported the results of a study for the 4Kscore Test’s clinical utility in reducing the number of prostate biopsies performed, while increasing the probability of detecting aggressive prostate cancer in men with abnormal prostate-specific antigen (PSA) levels and or digital rectal examination (DRE) results (Press release, Opko Health, FEB 9, 2016, View Source [SID:1234509014]). The peer-reviewed study, "The 4Kscore Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices", written by Badrinath Konety, MD, et al. and published in the January 2016 edition of Reviews in Urology, a MedReviews, LLC. Publication, which included 611 patients seen by 35 academic and community urologists across the United States, indicated that consideration of results from the 4Kscore tests led to 64.6% fewer prostate biopsies being performed among participating patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The 4Kscore test is a useful tool in identifying men with a significant risk of having an aggressive form of prostate cancer, who are most likely to benefit from a prostate biopsy and selective treatment or intensive intervention, while avoiding biopsies in men who are at low risk for developing aggressive disease," commented lead researcher Badrinath Konety, M.D., Dougherty Family Chair in Uro-Oncology and director of the Institute for Prostate and Urologic Cancers at the University of Minnesota. "Our findings suggest that PSA screening, when coupled with the 4Kscore test, can be made more specific, reduce biopsy complications and overtreatment, and be a more cost-effective solution for managing a patient’s prostate health."
Dr. Konety and colleagues evaluated the influence of the 4Kscore test on urologist-patient decisions about whether to perform a biopsy in men who had an abnormal PSA and or DRE result. Test results for patients were stratified into low risk ( < 7.5%), intermediate risk (7.5%-19.9%) and high risk (≥20%) for developing aggressive prostate cancer. Nearly half (49.3%) of the men were categorized as low risk; 25.7% and 25.0% fell into the intermediate-risk and high-risk categories, respectively. Notably, the 4Kscore test results influenced biopsy decisions in 88.7% of the men. In the three risk groups, a biopsy was avoided in 94.0%, 52.9%, and 19.0% of men in the low, intermediate, and high-risk categories, respectively.
A higher 4Kscore test result was significantly associated with a greater likelihood of having a prostate biopsy (P < 0.001). Among the 171 men who had a biopsy, 45 of the 104 cases (43.3%) with a high-risk 4Kscore test result (≥20% risk) were found to have aggressive prostate cancer upon prostate biopsy.
About the 4Kscore Test
The 4Kscore is the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer, the lethal form of prostate cancer. The 4Kscore test uses a proprietary algorithm that incorporates the blood levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and Human Kallikrein-2 (hK2), plus the patient’s age, and other clinical information to calculate the percentage risk (probability) of finding a Gleason Score 7 or higher grade of prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore Test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions and is included as a standard of care in the 2015 NCCN Prostate Cancer Early Detection Guidelines. The 4Kscore test provides individualized risk for the presence of aggressive prostate cancer and adds new information to the shared decision making discussion between the Urologist and the patient.